Study #2023-1002
A multicenter phase 1b/2 study of adagrasib, cetuximab, and cemiplimab for metastatic colorectal cancer harboring KRAS G12C mutations
MD Anderson Study Status
Enrolling
Treatment Agent
Cetuximab, Cemiplimab, Adagrasib
Description
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Colorectal Cancer, KRAS G12C Mutations
Study phase:
Physician name:
Christine Parseghian
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-927-2548
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.